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At ASTRO’s 2017 Annual Meeting in San Diego, CA, attendees were asked for the first time, 
“What is the most important research question that needs to be answered in the next 3-5 years?” 
This request was meant to start a dialogue, promote thoughtful discussion within our professional 
community, and help inform topics for ASTRO workshops and focus meetings.  There were 
nearly 550 responses in 2017 with the top 5 as follows: Immunotherapy/radiotherapy 
combination, genomic influences and targeted medicine, new clinical trial design, advanced 
imaging, and oligometastatic disease. In the subsequent years, ASTRO used these results to help 
guide future direction in several ways including forming think tanks and developing workshops. 
Think tanks were dedicated to biomarkers and nanotechnology in radiation oncology, the 
promises and pitfalls of genetic testing, and another on the genetic determinants in radiation 
oncology. Subsequent ASTRO Research Workshops deliberated the role of the tumor 
microenvironment, the influence of radiation on the immune response, and treatment of 
oligometastatic disease, highlighting the biology, clinical trials, and advances in imaging and 
physics relevant to the management of oligometastatic disease. 
 During ASTRO’s two subsequent meetings (2018, San Antonio and 2019, Chicago), attendees 
were asked yet again, “What is the One Big Discovery that needs to be translated into the clinic 
RIGHT NOW?”  Responses were quite varied, from “the increasing role of liquid biopsies,” to  
“enrolling in RO-ILS and enhancing our culture of safety,”  to “Ultra-High Dose Rate (FLASH) 
Radiotherapy…is it real or not?”  Averaging over the two years, approximately half of 
respondents were academic while half were in private practice.  There were 2.5 times more male 
respondents than female (71% vs. 29%) and most respondents practice domestically (90% vs. 
10%).  Millenials represented just 15% of respondents while Generation X and Baby Boomers 
were responsible for submitting the majority of responses, 48% and 35% respectively; for 
breakdown by year see Table 1. With 677 responses in 2018, the top 5 were: Immunotherapy 
(19%), Treatment for oligometastases (15%), SBRT (11%), Hypofractionation (6%), and Liquid 
Biopsies (3%).  In 2019 there were 730 responses, the top 5 of which were: FLASH (15%), 
Immunotherapy (12%), SBRT (5%), Enhanced data (3%), and Treatment for oligometastases 
(3%). The most frequently referenced cancer treatment sites in the 2017 initial survey were 
prostate and breast; interestingly this finding persisted in 2018 and 2019 as well.  In 2018 all age 
groups ranked immunotherapy first but 1 year later Millennial and Generation X respondents 
now ranked FLASH radiotherapy first while Baby Boomers stood fast with immunotherapy. 
 
And so, what is the One Big Discovery that needs to be translated into the clinic RIGHT NOW?  
In an attempt at synthesizing the spirit behind the top choices from 2018 and 2019, it seems that 
our membership continues to see significant value in radiation therapy (be it hypofractionated or 
stereotactic ablative) as a tool that can be increasingly utilized to target disease in patients with 
metastatic or limited metastatic disease and the potential of new delivery techniques like 
FLASH. Given the ongoing positive response, and the informative variation in trends from year 
to year, we will ask this question yet again at the 2020 Annual Meeting via virtual platform 
except with separate radiobiology, physics, and clinical components: 
 
1)           What is the 1 Big Radiobiology Discovery that needs to be translated into clinic care 
RIGHT NOW? 
 
2)           What is the 1 Big Medical Physics Discovery that needs to be translated into clinical 
care RIGHT NOW? 
 
3)           What is the 1 Big Clinical Discovery that needs to be translated into clinical care 
RIGHT NOW? 
   















Hospital-based 70% 74% 73% 75% 
Freestanding/Satellite clinic 24% 23% 22% 22% 
I practice less than three days 
a week 
3% 2% 3% 2% 
Commercial entity 3% 1% 2% 1% 









Academic/University system 42% 46% 42% 49% 
Private practice/Community-
based system 
42% 43% 43% 41% 
Government/Public sector 8% 6% 8% 6% 
Independent 
contractor/Locum tenens 
4% 3% 3% 2% 
Industry 2% 1% 3% 1% 
My employer doesn't fall on 
this list 
2% 1% 1% 1% 









Domestic 94% 76% 86% 75% 










South 30% 33% 26% 35% 
Northeast 25% 22% 28% 22% 
West 25% 22% 19% 21% 










Male 73% 69% 69% 70% 










Millennial, 1981-1996 14% 19% 16% 24% 
Gen X, 1965-1980 46% 41% 49% 40% 
Baby Boomers, 1946-1964 36% 38% 34% 35% 
Silent, 1945 or earlier 5% 2% 1% 2% 
a 
2018 Sampling frames: Respondents n=677; ASTRO Membership Survey n=8427 
b 
2019 Sampling frames: Respondents n=730; ASTRO Membership Survey n=8292 
 
 
